Trade Idea: Long UltraGreen.AI; Concerns over new entrants look overdone

TLDR; Long UltraGreen.AI at S$0.895, with conservative sizing given binary nature of competitive risk. The trade is premised on the market having priced in a more severe deterioration in average selling prices (ASP) and volumes than we think is likely. Key upside catalysts are: 1) evidence that Zydus Lifesciences and Provepharm are unable or unwilling to materially undercut UltraGreen.AI alongside 2) continued growth in fluorescence-guided surgery (FGS) adoption, allowing a larger overall market to offset potential share loss.

Attractive set-up – Stock is down 40% on new entrants threatening its “monopoly” status

UltraGreen.AI has fallen c.40% over the past month as its previously dominant position in the US Indocyanine Green (ICG) market has come under threat following FDA approvals of competing ICG products from Zydus and Provepharm. With the US accounting for c.75% of UltraGreen.AI’s revenue, the changing competitive landscape is particularly significant for the company’s earnings outlook, with investors now pricing in a combination of lower ASP and volume/market-share losses into 2027e and beyond.

We also think sentiment is at an all-time low, particularly after DBS (UltraGreen.AI's lead underwriter for their recent IPO) downgraded the stock.

Despite a still strong 1H26 earnings (e.g., +57% YoY on net profit) and positive guidance reiterated, UltraGreen.AI’s competitive landscape could shift from an almost "monopoly" (e.g., UltraGreen.AI currently has 83% market share in the US) towards one facing multiple potential generic entrants.

• Zydus represents the most immediate competitive threat, given its FDA-approved generic ICG product, approved 3 August 2026.
• Provepharm provides an additional potential source of competition as it expands into the US. The product has already been launched in the UK, with Provepharm targeting further US expansion. Provepharm received FDA approval for Zyogreen on 10 July 2026.
• Stryker remains the key incumbent competitor, although its SPY Agent Green ICG is primarily used alongside Stryker’s proprietary fluorescence imaging systems, making its offering more integrated and less directly comparable to UltraGreen.AI’s standalone ICG product.

Share price reaction likely overblown because...

(1) Volume downside may be more manageable than anticipated‍

We believe the potential decline in volumes could be partly offset by the significant growth runaway for fluorescence-guided surgery (FGS). Among established procedures (e.g., cholecystectomy), FGS penetration remains below 30% even in the US, at c.20% in Europe and negligible across most of Asia. This is excluding emerging procedures that could further expand the addressable market. This leaves considerable room for the overall ICG market to expand, potentially allowing multiple players to coexist and grow together. Overall, growing the overall size of the pie can cushion some of the anticipated impact from market share erosion. Ironically, the new entrants could even help accelerate penetration, as we have seen in sectors like e-commerce.

‍(2) ASP pressure may also be overstated‍

The entry of Zydus and Provepharm creates a clear risk of pricing pressure, particularly given that Provepharm’s Zyogreen is supplied as a ready-to-use solution rather than requiring reconstitution. However, we believe price sensitivity may be less significant than the market currently implies. At c.US$150 per vial, ICG represents only c.1-2% of the total surgical bill. Even a >50% reduction in the cost of ICG would therefore generate savings of only around US$75, or less than 1% of the overall procedure cost. Given the relatively small contribution of ICG to total surgical costs, hospitals and surgeons may place greater emphasis on UltraGreen.AI's clinical track record, supply track record, and surgeon familiarity vs price alone.

‍(3) Valuation provides a degree of downside support. 13-14x 27E P/E even with nightmare scenario built in ‍

At approximately S$0.90, UltraGreen.AI still trades at a relatively undemanding c.13-14x 2027E P/E even under a conservative scenario where we assume a 30% reduction in both ASPs and volumes (Note: FDA's broad rule of thumb is that one generic competitor can lead to c.30% price reductions). This suggests that a meaningful degree of competitive disruption is already reflected in the current valuation, while any outcome better than these assumptions could provide significant upside. If Zydus and Provepharm ultimately achieve slower-than-expected commercial penetration, or if the overall ICG/FGS market expands sufficiently to absorb additional players, UltraGreen.AI could see a meaningful recovery from current levels.

‍Competitive pressure remains a key risk nonetheless

The key risk is that Zydus and Provepharm price aggressively and gain US market share faster than expected, pressuring UltraGreen.AI’s ASPs and volumes. While Zydus benefits from 180-day exclusivity applicable to qualifying Abbreviated New Drug Applications (ANDAs), Provepharm’s 505(b)(2) approval does not carry the same exclusivity. With c.75% of UltraGreen.AI’s revenue from the US, faster than expected adoption by either competitor could materially impact earnings and undermine the mean-reversion thesis. Key watchpoints: Zydus US launch + selling price, whether GPOs/hospitals add them into procurement list, UltraGreen.AI's reaction.

‍Overall, we think UGS looks attractive given the recent sell-off

Competitive uncertainty around Zydus and Provepharm will remain an overhang until there is greater clarity on pricing, capacity, distribution and customer adoption. That said, we note that FDA approval alone does not guarantee rapid commercial penetration. We believe the recent sell-off is overdone, reflecting concerns that have yet to translate into meaningful deterioration in UltraGreen.AI’s earnings or operating performance. This disconnect presents an opportunistic, high-risk/high-reward mean-reversion trade, with a small position offering exposure to a potential re-rating if competitive disruption proves less severe than feared, while aggressive pricing or rapid market-share gains by new entrants would invalidate the thesis.

‍

FGS = Fluorescence Guided Surgery. A fluorescent dye is injected into the patient, and a near-infrared camera detects the fluorescence in real time. This helps surgeons visualise features that may be difficult to distinguish with the naked eye, such as blood vessels, blood flow and tissue perfusion.

ICG = Indocyanine Green. The fluorescent dye injected into the patient to enable fluorescence imaging during FGS. It is commonly used to assess blood flow and tissue perfusion.